Clinical trials: psoriasis
Palmoplantaris Pustulosis
A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
The purpose of this study is to assess the efficacy, safety, and tolerability of CNTO 1959 following subcutaneous administration in participants with palmoplantar pustulosis.
- Trial name
- NCT01845987
- Testing
- CNTO 1959
- Where
- 8 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Janssen Pharmaceutical K.K.
Rheumatoid Arthritis, Ankylosing Spondylitis
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
The aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of HUMIRA® in routine clinical use in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01083693
- Where
- 20 sites in Austria
- Volunteers
- 162 people
- Sponsor
- Abbott
Psoriasis
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
- Trial name
- NCT06701513
- Testing
- Deucravacitinib
- Where
- 48 sites in France, Switzerland
- Volunteers
- 350 people
- Sponsor
- Bristol-Myers Squibb
Eczema, Psoriasis
Evidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring
Over 300 million people around the world struggle with skin conditions like eczema and psoriasis, which cause ongoing discomfort and emotional stress.
- Trial name
- NCT07846813
- Testing
- Vibroacoustic sensing device
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Edinburgh
Psoriasis
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
The purpose of this study is to evaluate the potential effects of a single dose of 200 milligram (mg) guselkumab on the plasma concentrations of a cocktail of representative probe substrates of Cytochrome P450 isozymes (CYP3A4…
- Trial name
- NCT02397382
- Testing
- Guselkumab, Midazolam, Warfarin
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Janssen Research & Development, LLC
Axial Spondyloarthritis, Psoriatic Arthritis
RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis
Unlike other rheumatic diseases, acute phase reactants such as C-reactive protein and erythrocyte sedimentation rate are not diagnostic for patients with Spondyloarthropathies (SpA).
- Trial name
- NCT05771389
- Testing
- serum raftlin-1 protein levels
- Where
- Turkey (Türkiye)
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Pilot Study, Psoriasis
Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis
A pilot study on the formulation of topical methotrexate was conducted. Patients after baseline evaluation were randomly placed into either topical 1% methotrexate gel or clobetasol propionate 0.05% ointment which was applied for…
- Trial name
- NCT06555497
- Testing
- topical 1% methotrexate gel, clobetasol propionate 0.05% ointment
- Where
- Philippines
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium
Psoriasis of Scalp
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis
The purpose of the trial is to study the safety and efficacy of long term use of once daily applications, as needed, of calcipotriol plus betamethasone dipropionate gel, as compared to calcipotriol alone in the same gel.
- Trial name
- NCT00216879
- Testing
- Calcipotriol plus betamethasone dipropionate gel (LEO 80185)
- Where
- 5 sites in Canada, Denmark and 3 more
- Volunteers
- 800 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
This study is designed to evaluate the efficacy and safety of Prurisol using three different oral daily dose regimens administered to subjects with active mild to moderate chronic plaque psoriasis.
- Trial name
- NCT02494479
- Testing
- Prurisol
- Where
- 9 sites in United States
- Volunteers
- 115 people
- Sponsor
- Cellceutix Corporation
Plaque Psoriasis
Safety and Efficacy Study of CF101 to Treat Psoriasis
This study will test the hypothesis that CF101, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis.
- Trial name
- NCT00428974
- Testing
- CF101 1mg, CF101 2mg, CF101 4mg
- Where
- 4 sites in Israel
- Volunteers
- 76 people
- Sponsor
- Can-Fite BioPharma
Inflammatory Arthritis, Ankylosing Spondylitis
Impact of Barriers and Facilitators to Physical Activity in Patients With Inflammatory Arthritis
Background: Patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA) are more prone to physical inactivity but derive specific benefits from regular…
- Conditions
- Inflammatory Arthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis
- Trial name
- ImBAIA (NCT04426747)
- Testing
- No intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Severe Plaque Psoriasis in Chinese Children
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint…
- Trial name
- NCT07529925
- Testing
- Adalimumab Solution for Injection
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Plaque Psoriasis
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the…
- Trial name
- NCT06030076
- Testing
- Tildrakizumab
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Almirall, S.A.
Psoriasis, Administration, Topical
Microneedle Patch for Psoriatic Plaques
The purpose of this study is to evaluate the efficacy of microneedle patch on the psoriatic plaques.
- Trial name
- NCT02955576
- Testing
- Microneedle HA patch, Patch, Control
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- The Catholic University of Korea
Psoriasis
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
- Trial name
- NCT03827876
- Testing
- Enstilar 0.005%-0.064% Topical Foam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
This multicenter, post marketing observational study (PMOS) was designed to evaluate the effectiveness of adalimumab over a period of 9 months as determined by the Psoriasis Area and Severity Index (PASI) in participants with…
- Trial name
- EPIC (NCT01401452)
- Volunteers
- 246 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
LAS41008 in Moderate to Severe Chronic Plaque Psoriasis
The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis
- Trial name
- NCT01726933
- Testing
- LAS41008, LASW1835
- Where
- 4 sites in Austria, Germany and 2 more
- Volunteers
- 839 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
- Trial name
- NCT05739435
- Testing
- envudeucitinib
- Where
- 38 sites in United States, Canada
- Volunteers
- 165 people
- Sponsor
- Alumis Inc
Spondylitis, Ankylosing, Arthritis, Psoriatic
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
- Trial name
- NCT03733925
- Testing
- Golimumab
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Private Limited
Inflammatory Disease, Drug Side Effect
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic…
- Conditions
- Inflammatory Disease, Drug Side Effect, Drug Use, Adverse Drug Event
- Trial name
- LOOK-UP (NCT06498167)
- Testing
- Upadacitinib
- Where
- 3 sites in Portugal
- Volunteers
- 150 people
- Sponsor
- Universidade do Porto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.